Dianthus Therapeutics DNTH EBIT

EBIT at other companies

Johnson & JohnsonJNJ

$7.14B+7.4%

AmgenAMGN

$3.51B+32.3%

AnaptysBio, Inc.ANAB

-$34.64M-25.8%

Vor BiopharmaVOR

-$35.16M-5.6%

Cullinan Therapeutics, Inc.CGEM

-$57.25M+24.5%

Shattuck Labs, Inc.STTK

-$16.16M-24.0%

FAQ

What is Dianthus Therapeutics's EBIT?

Dianthus Therapeutics (DNTH) reported EBIT of -$46.53M in Q1 2026.

How has Dianthus Therapeutics's EBIT changed year-over-year?

Dianthus Therapeutics's EBIT decreased by 40.3% year-over-year, from -$33.18M to -$46.53M.

What is the long-term trend for Dianthus Therapeutics's EBIT?

Over 3 years (2021 to 2024), Dianthus Therapeutics's EBIT has grown at a 10.9% compound annual growth rate (CAGR), from -$74.69M to -$101.86M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.